-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Oncorus (NASDAQ:ONCR) Stock Rating Lowered by Piper Sandler
Oncorus (NASDAQ:ONCR) Stock Rating Lowered by Piper Sandler
Piper Sandler cut shares of Oncorus (NASDAQ:ONCR – Get Rating) from an overweight rating to a neutral rating in a research report released on Wednesday, The Fly reports. Piper Sandler currently has $2.00 target price on the stock, down from their prior target price of $6.00.
Oncorus Trading Up 2.1 %
Shares of ONCR stock opened at $0.46 on Wednesday. The business's fifty day moving average price is $0.69 and its 200 day moving average price is $1.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.97 and a quick ratio of 4.97. The firm has a market capitalization of $11.93 million, a PE ratio of -0.16 and a beta of 2.24. Oncorus has a 1-year low of $0.41 and a 1-year high of $6.08.
Get Oncorus alerts:Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ONCR. Goldman Sachs Group Inc. lifted its stake in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock valued at $148,000 after purchasing an additional 30,668 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Oncorus during the second quarter worth $476,000. Renaissance Technologies LLC lifted its holdings in Oncorus by 23.9% in the second quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Sawtooth Solutions LLC lifted its holdings in shares of Oncorus by 22.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 77,336 shares of the company's stock worth $97,000 after purchasing an additional 14,433 shares during the last quarter. Finally, Private Advisor Group LLC boosted its holdings in shares of Oncorus by 28.9% during the second quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock valued at $103,000 after acquiring an additional 18,220 shares during the period. Institutional investors and hedge funds own 65.89% of the company's stock.
Oncorus Company Profile
(Get Rating)Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Featured Stories
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
Piper Sandler cut shares of Oncorus (NASDAQ:ONCR – Get Rating) from an overweight rating to a neutral rating in a research report released on Wednesday, The Fly reports. Piper Sandler currently has $2.00 target price on the stock, down from their prior target price of $6.00.
据The Fly报道,派珀·桑德勒在周三发布的一份研究报告中将安可乐斯(纳斯达克代码:ONCR-GET Rating)的股票评级从增持下调至中性。派珀·桑德勒目前对该股的目标价为2.00美元,低于此前6.00美元的目标价。
Oncorus Trading Up 2.1 %
Oncorus交易上涨2.1%
Shares of ONCR stock opened at $0.46 on Wednesday. The business's fifty day moving average price is $0.69 and its 200 day moving average price is $1.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.97 and a quick ratio of 4.97. The firm has a market capitalization of $11.93 million, a PE ratio of -0.16 and a beta of 2.24. Oncorus has a 1-year low of $0.41 and a 1-year high of $6.08.
周三,ONCR的股票开盘报0.46美元。该业务的50日移动均线价格为0.69美元,200日移动均线价格为1.10美元。该公司的债务权益比为0.24,流动比率为4.97,速动比率为4.97。该公司市值为1,93万美元,市盈率为-0.16,贝塔系数为2.24。Oncorus的一年低点为0.41美元,一年高位为6.08美元。
Institutional Inflows and Outflows
机构资金流入和流出
Several institutional investors have recently added to or reduced their stakes in ONCR. Goldman Sachs Group Inc. lifted its stake in shares of Oncorus by 35.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 117,925 shares of the company's stock valued at $148,000 after purchasing an additional 30,668 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Oncorus during the second quarter worth $476,000. Renaissance Technologies LLC lifted its holdings in Oncorus by 23.9% in the second quarter. Renaissance Technologies LLC now owns 217,450 shares of the company's stock worth $274,000 after acquiring an additional 41,918 shares during the last quarter. Sawtooth Solutions LLC lifted its holdings in shares of Oncorus by 22.9% in the 2nd quarter. Sawtooth Solutions LLC now owns 77,336 shares of the company's stock worth $97,000 after purchasing an additional 14,433 shares during the last quarter. Finally, Private Advisor Group LLC boosted its holdings in shares of Oncorus by 28.9% during the second quarter. Private Advisor Group LLC now owns 81,304 shares of the company's stock valued at $103,000 after acquiring an additional 18,220 shares during the period. Institutional investors and hedge funds own 65.89% of the company's stock.
几家机构投资者最近增持或减持了ONCR的股份。高盛股份有限公司在第二季度增持了安可仕35.1%的股份。高盛股份有限公司在上个季度增持了30,668股后,目前持有117,925股该公司股票,价值148,000美元。Millennium Management LLC在第二季度收购了Oncorus价值47.6万美元的新股份。复兴科技有限责任公司在第二季度增持了23.9%的Oncorus股份。复兴科技有限责任公司在上个季度增持了41,918股后,现在拥有217,450股该公司股票,价值27.4万美元。锯齿解决方案有限责任公司在第二季度增持了22.9%的Oncorus股票。锯齿解决方案有限责任公司现在拥有77,336股该公司股票,价值97,000美元,在上个季度又购买了14,433股。最后,Private Advisor Group LLC在第二季度增持了28.9%的Oncorus股票。Private Advisor Group LLC在此期间额外收购了18,220股票,目前拥有81,304股该公司股票,价值103,000美元。机构投资者和对冲基金持有该公司65.89%的股票。
Oncorus Company Profile
Oncorus公司简介
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Oncorus,Inc.是一家临床阶段的生物制药公司,专注于为癌症患者开发病毒免疫疗法。该公司的主要候选产品是ONCR-177,这是一种肿瘤内注射的病毒免疫疗法,基于其溶瘤的单纯疱疹病毒1型平台,该平台正处于治疗各种癌症的I期临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取StockNews.com关于Oncorus的研究报告(ONCR)
- 为什么CSL有限公司的股票值得一看
- MarketBeat:回顾一周11/28-12/02
- Okta Inc.庆祝收益节节攀升,但他们能持续这种提振吗?
- 机构正在购买安巴雷拉,你应该吗?
- ZIM能否抵御集装箱航运业的普遍低迷?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
接受Oncorus Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Oncorus和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧